An emerging technique for the dual‑targeting chemo‑radio‑ablation of generic micro‑cancers in conjunction with cancer liquid biopsy

Cancer liquid biopsy (CLB) aims for the detection of circulating tumor cells, cell‑free DNA or RNA, and specifically expressed proteins, lipids and metabolites present in the bio‑fluids of patients. Rapid advances in technologies for sampling such bio‑specimens and for genomic sequencing have fostered the development of authority‑approved CLB tests in clinical practice for the early screening and diagnosis of malignancies. However, perhaps some solid tumors could have been reliably detected using CLB, while they were still too small to be found in patients using currently available imaging technologies. This could impose troublesome clinical scenarios. In this communication article, the author would like to propose a potential solution that eventually may be used to combat such unwanted embarrassing clinical issues by using one episode of targeted radiotheragnostics, namely OncoCiDia.

Medienart:

E-Artikel

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Zur Gesamtaufnahme - volume:49

Enthalten in:

Oncology reports - 49(2023), 2 vom: 01. Feb.

Sprache:

Englisch

Beteiligte Personen:

Ni, Yicheng [VerfasserIn]

Links:

Volltext

Themen:

63231-63-0
Biomarkers, Tumor
Cancer liquid biopsy
Cell-Free Nucleic Acids
Journal Article
Micro‑cancers
OncoCiDia chemo‑radio‑ablation
Pan‑anticancer
RNA
Radiotheragnostics
Targeted radiotherapy

Anmerkungen:

Date Completed 30.12.2022

Date Revised 03.01.2023

published: Print-Electronic

Citation Status MEDLINE

doi:

10.3892/or.2022.8472

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM350910391